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charge for pharmaceuticals of MRSA bacteremia patients was
$2411 and that of MSSA bacteremia patients was $1289. The
median length of hospitalization after the development of MRSA
patients who survived was 32.5 days and that of MSSA bac-
teremia control patients who survived was 18 days. CONCLU-
SION: Antibiotic resistance in Staphylococcus aureus bacteremia
increased direct medical cost by 26%. The results of this study
indicate that the MRSA infection is associated with increased
medical cost and prolonged hospital stay.
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OBJECTIVES: Zidovudine (ZDV) use has been shown to be
associated with anemia. Our objective was to assess the impact
of anemia on medical resource use and cost in patients treated
with a ZDV-containing HAART regimens. METHODS: Case-
control study using HIV Insight, which contains medical chart
data from 21 US HIV care centers. ZDV-naïve patients who
began a ZDV-containing HAART regimen on any date from
January 2000 to June 2004 were assessed for baseline anemia
(Hb < 11 g/dL). Those without anemia (N = 529) were followed
through June, 2005 or until they had anemia or changed to a
non-ZDV-containing regimen. Those with anemia (N = 69) were
followed until anemia worsened (drop ≥ 1.0 g/dL). Patients with
an incident anemia event (initiating or worsening) with ≥12
months of follow-up were selected as cases. Controls were
matched on baseline anemia, CD4 < 350, gender and time
period. Medical resource use was tabulated during the 1-year
post anemia period. Costs were estimated for health care encoun-
ters using external data for prices expressed in 2006 $US.
RESULTS: Cases included 70 patients with anemia (57 initiat-
ing, 13 worsening.) Cases had greater use of medical resources
than controls: 9.2 vs 5.0 (P < 0.001) ofﬁce visits per year, 33%
vs 3% hospitalized (P < 0.001), 21% vs 3% treated with EPO
(P = 0.001) and 7% vs 0% (P = 0.058) with a transfusion. Cases
had higher average annual costs than controls; $37,124 vs
$25,141 (P = 0.002). Cost components included EPO $1,369 vs
$181 (P = 0.002), antiretrovirals $18,299 vs $19,837 (P =
0.461), other drugs $12,488 vs $3,763 (P = 0.005) and hospital
stays, $3,114 vs $169 (P < 0.001). CONCLUSION: Patients
treated with ZDV who experienced anemia required signiﬁcantly
more medical care and reported higher medical cost than patients
without anemia.
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OBJECTIVES: Determine the economic impact and resource uti-
lization of adult HIV and HCV co-infected hemophilia patients
in a managed care population in the United States. METHODS:
Retrospective claims database analysis from 1/97 to 4/04.
Patients continuously enrolled for at least 6 months and >18
years of age were included. Hemophilia patients were identiﬁed
using ICD-9CM, HCPCS, and NDC codes. Four cohorts for
analysis were established: Hemophilia only Hemophilia + HIV,
Hemophilia + HCV, Hemophilia + HIV + HCV. The main out-
comes of study were costs associated with all pharmacy and
medical claims, inpatient hospitalizations (frequency and length
of stay) and ofﬁce visit distribution by physician specialty.
RESULTS: Annual cost of care was $85,616 for the hemophilia
only cohort, $99,180 for the HIV cohort, $105,676 for the HCV
cohort and $129,889 for HIV/HCV co-infected cohort in 2004
dollars. Clotting factor accounted for approximately 70–81% of
total costs. The Hemophilia only, HCV, HIV, HIV/HCV infected
hemophilia cohorts had prescription drug costs of $2,341,
$8,867, $6,256 and $12,060, respectively. Approximately 17%
of hemophilia only, 19% of HCV, and 27% of the HIV/HCV
cohorts were hospitalized during the study period (p = 0.45).
Hospitalizations that were hemophilia related accounted for
43% of total hospitalizations for the hemophilia only cohort and
16% for the HIV/HCV cohort (p = 0.30). No signiﬁcant differ-
ence in inpatient length of stay was found. There was a differ-
ence in the mean number of ofﬁce visits among the cohorts (p =
0.022) with the HIV/HCV cohort having more visits than the
hemophilia only group, 18.3 vs. 7.3, respectively (p = 0.05).
CONCLUSION: Although we were not able to control for sever-
ity, the presence of HIV and HCV co-infection in hemophiliacs
is associated with an increase in annual costs by up to 52%.
Increased clotting factor use and prescription drug costs in the
virally infected groups account for most of the increase in costs.
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OBJECTIVES: To estimate the long-term health and economic
impact of managing CHB with entecavir instead of adefovir
treatment in the US, based upon projected clinical beneﬁts from
HBV DNA reduction observed in trials. METHODS: We took
the perspective of a comprehensive payer responsible for all
direct health care expenditures. A decision simulation model was
developed to consider a hypothetical cohort of 1000 lamivudine
refractory CHB patients. Multivariate-adjusted relative risks for
ﬁve HBV DNA categories were derived from the published
R.E.V.E.A.L.-HBV study. These results were applied to the
patients with simulation of their HBV DNA data derived from
summary statistics reported in separate entecavir and adefovir
clinical trials. Entecavir and Adefovir daily costs were assumed
$20.52 and $19.11 based on the wholesale acquisition prices.
Life expectancy estimates, direct medical cost of and utility
scores for different phases of CHB were estimated from pub-
lished US speciﬁc data. Viral resistance due to treatment was
included. RESULTS: Entecavir was superior to adefovir for the
mean reduction in serum HBV DNA by PCR assay (log10
copies/mL) adjusted for lamivudine effect, with reductions of
4.97 versus 4.00, respectively. More patients reached unde-
tectable viral load level with entecavir than adefovir treatment
at Week 48 (19.5% vs 9.6%). In the reference case, for 1000
patients aged 40 years, compared with adefovir, ten years of ente-
cavir treatment avoided 25 compensated cirrhosis, 3 decompen-
sated cirrhosis, and 15 HCC, resulting in 0.235 quality-adjusted
life year (QALY) gain at an incremental cost of $2563 per patient
(3% discounted). The incremental cost of using entecavir was
